Chiu, Christopher

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 1,445

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2019) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 1,045

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Thieblemont, C., Phillips, T., Ghesquieres, H., Cheah, C. Y., Clausen, M. R., Cunningham, D., Do, Y. R., Feldman, T., Gasiorowski, R., Jurczak, W., et al. (2023) · Journal of Clinical Oncology

Lymphoma Diagnosis and TreatmentCAR-T cell therapy research

Cited by 584

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

Hutchings, M., Mous, R., Clausen, M. R., Johnson, P., Linton, K. M., Chamuleau, M. E. D., Lewis, D. J., Sureda Balari, A., Cunningham, D., Oliveri, R. S., et al. (2021) · The Lancet

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 337

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting

Mhibik, M., Gaglione, E. M., Eik, D., Herrick, J., Le, J., Ahn, I. E., Chiu, C., Wielgos-Bonvallet, M., Hiemstra, I. H., Breij, E. C. W., et al. (2023) · Blood Advances

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 43

Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas

Li, T., Hiemstra, I. H., Chiu, C., Oliveri, R. S., Elliott, B., DeMarco, D., Salcedo, T., Egerod, F. L., Sasser, K., Ahmadi, T., et al. (2022) · Clinical Pharmacology & Therapeutics

Monoclonal and Polyclonal Antibodies ResearchLymphoma Diagnosis and Treatment

Cited by 34

Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B-Cell Lymphoma.

Li, T., Gibiansky, L., Parikh, A., Putnins, M., Chiu, C. W., Sacchi, M., Feng, H., Ahmadi, T., Gupta, M., & Xu, S. (2025) · Clinical Pharmacology & Therapeutics

Lymphoma Diagnosis and TreatmentMonoclonal and Polyclonal Antibodies Research

Cited by 7